Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-10
2008-09-23
Kosar, Andrew D. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C600S595000
Reexamination Certificate
active
07427601
ABSTRACT:
The present invention is directed to the use of a class of peptide compounds for treating essential tremor and other tremor syndromes.
REFERENCES:
patent: 5378729 (1995-01-01), Kohn et al.
patent: 5773475 (1998-06-01), Kohn
patent: 6197764 (2001-03-01), Bradley et al.
patent: 6277825 (2001-08-01), Olivera et al.
patent: 6884910 (2005-04-01), Harris
patent: 2003/0180332 (2003-09-01), Rimpler et al.
patent: 2005/0227961 (2005-10-01), Speicher
patent: 2005/0261204 (2005-11-01), Stoehr
patent: 2005/0277596 (2005-12-01), Stoehr
patent: 1 486 205 (2004-12-01), None
patent: 1 486 206 (2004-12-01), None
patent: WO 00/51586 (2000-09-01), None
patent: WO 02/15922 (2002-02-01), None
patent: WO 02/42256 (2002-05-01), None
patent: WO 02/74297 (2002-09-01), None
patent: WO 02/74784 (2002-09-01), None
patent: WO 2004/046178 (2004-06-01), None
“Retrieved from” http://www.wrongdiagnosis.com/sym/tremor—symptoms.htm) 2003, [retrived on Aug. 23, 2006].
“Retrieved from”, www.jstage.jst.go.jp/article/yakushi/121/4/121—259/—article/-char/en, [retriecved on Aug. 22, 2006], Suemaru, et al., Yakugaku Zasshi, 2001, vol. 121, 259-264, (abstract only).
“Retrieved from” http://www.healthatoz.com/healthatoz/Atoz/dc/caz
eur/park/park—gen—prev.jsp Jun. 2006, [retrieved on Aug. 24, 2006].
“Retrieved from” http://www.ninds.nih.gov/disorders/tremor/tremor.htm Jul. 2006, [retrieved on Aug. 22, 2006].
[Retrived from website] ‘http://www.answers.com/topic/prevent’, 4 pages [retrieved on Jan. 22, 2007].
Suemaru, et al., Yakugaku Zasshi, 2001, vol. 121, 21 pages [Translation].
Bialer, et al., 2002, Epilepsy Research 51, 31-71.
Hovinga, IDrugs 6(5):479-485, 2003.
Arroyo (2003) “Safety of SPM 927 in subjects with epilepsy and neuropathic pain” Poster presented at AES Scientific Exhibit, Dec. 5-10, 2003.
Baisara (1982) Ind. J. Physiol. Pharmacol. 26(3): 184-195.
Beyreuthe et al. (2007) CNS Drug Rev. 13(1):21-42.
Brodie (1996) Can. J. Neurol. Sci. 23(Suppl. 2):S6-S9.
Daniels et al. (2005) “Long-term safety and efficacy of lacosamide as adjunctive therapy in subjects with partial seizures: 96-week follow-up” Poster presented at AES Scientific Exhibit, Dec. 2-5, 2005.
Domino & Sheng (1993) J. Pharmacol. Exp. Ther. 264(1):221-225.
Doty et al. (2004) “Update on the clinical development of SPM 927 (formerly harkoseride)” Presented at EILAT VII, May 2004.
Duncan & Kohn (2005) Epilepsy Res. 67:81-87.
Fleminger (1999) Therapeutics 2(4):118.
Hidvegi et al. (2006) “Lacosamide in subjects with painful distal diabetic neuropathy: results of multi-center, open-label, follow-on trial” Poster presented at American Pain Society, May 3-6, 2006.
Kenney et al. (2006) http://www.ampainsoc.org/db2/abstract/view?poster—id=2773#774.
Mar. (1985) Advanced Organic Chemistry, New York: Wiley, pp. 16-18.
Porter et al. (1984) Cleveland Clinic Quarterly 51(2):293-305.
Rauck et al. (2007) Clin. J. Pain 23(2):150-158.
Sachdeo et al. (2003) “An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures” Poster presented at 55th Annual Meeting, American Academy of Neutology, Mar. 2003.
Shaibani et al. (2005) “An open-label follow-on trial to assess the long-term safety and efficacy of oral lacosamide in subjects with diabetic neuropathy” Poster presented at World Congress on Pain, Aug. 21-26, 2005.
Sommerville (2003) “Schwarz Pharma's Neurology Pipeline” http://www.schwarzpharma.com/—uploads/assets/1369—4—neurology—KNS—190203.pdf.
Stables & Kupferberg (1997) in Avanzani et al. “Molecular and Cellular Targets for Antiepileptic Drugs”, chap. 16, pp. 191-198; London: Libbey.
Wymer et al. (2005) “A multi-center, randomized double-blind, placebo-controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy,” 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, Nov. 3-5, 2005.
Gudibande Satyanarayana
Harness & Dickey & Pierce P.L.C.
Kosar Andrew D.
Schwarz Pharma AG
LandOfFree
Method for treating tremor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating tremor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating tremor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982578